title: PRO-051, an antisense oligonucleotide for the potential treatment of Duchenne muscular dystrophy.
abstract: PRO-051 (GSK-2402968), being developed by GlaxoSmithKline plc, under license from Leiden University Medical Center and Prosensa Therapeutics BV, is a 2'-O-methyl phosphorothioate antisense oligonucleotide for the potential treatment of Duchenne muscular dystrophy (DMD). The PRO-051 oligonucleotide sequence induces skipping of exon 51 of the dystrophin gene by binding to a sequence within the dystrophin pre-mRNA and masking the exon inclusion signals that are used for splicing. Removal of exon 51 from an exon 45 to 50, 47 to 50, 48 to 50, 49 to 50, 50, 52 or 52 to 63 deleted transcript allows restoration of the open reading frame and synthesis of an internally truncated, semi-functional dystrophin protein. By targeting exon 51, approximately 13% of patients with DMD could be treated, the largest proportion of patients that could benefit from targeting a single dystrophin exon. A proof-of-concept clinical trial of PRO-051 in patients with DMD demonstrated that a single intramuscular administration of PRO-051 induced exon skipping within muscle fibers adjacent to the injection site, while biopsies revealed dystrophin expression in treated but not control muscle fibers. At the time of publication, a phase I/IIa trial to evaluate subcutaneous delivery of PRO-051 had been completed, although full results were yet to be published.
authors.affiliation: Oxford University, Department of Physiology, Anatomy and Genetics, Le Gros Clark Building, South Parks Road, Oxford OX1 3QX, UK.
authors.forename: Suzan M
authors.initials: SM
authors.lastname: Hammond
authors.forename: Matthew Ja
authors.initials: MJ
authors.lastname: Wood
mesh_terms: D004353:Drug Evaluation, Preclinical; D006801:Humans; D020388:Muscular Dystrophy, Duchenne / Q000188:drug therapy*; D009841:Oligonucleotides / Q000009:adverse effects / Q000138:chemical synthesis / Q000493:pharmacokinetics / Q000627:therapeutic use*; D016376:Oligonucleotides, Antisense / Q000009:adverse effects / Q000138:chemical synthesis / Q000493:pharmacokinetics / Q000627:therapeutic use*; D010330:Patents as Topic; D013329:Structure-Activity Relationship
chemical_list: D009841:Oligonucleotides; D016376:Oligonucleotides, Antisense; C525434:PRO051